Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,treasuryStock,otherStockholderEquity,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,WC,language,region,quoteType,quoteSourceName,triggerable,currency,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,fullExchangeName,financialCurrency,regularMarketOpen,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,regularMarketChange,regularMarketChangePercent,regularMarketTime,regularMarketPrice,regularMarketDayHigh,regularMarketDayRange,regularMarketDayLow,regularMarketVolume,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeDataDelayedBy,ipoExpectedDate,averageAnalystRating,tradeable,marketState,firstTradeDateMilliseconds,priceHint,exchange,longName,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,displayName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,DAWN,311763000.0,61928900,9914000,,-15473000,,-14282000,5525000,0,-15439000,-15439000,,-7000,,,,0,0,15439000,0,-34000,,-15473000,-114276000,4774000.0,311763000.0,709000.0,316537000.0,398071000.0,1277000.0,-86308000.0,126000.0,309996000.0,4662000.0,386000.0,316025000.0,348000.0,,,-339000.0,168532000.0,-186000.0,167660000.0,155126000.0,-13406000.0,49000.0,872000.0,1354000.0,,,311363000.0,en-US,US,EQUITY,Nasdaq Real Time Price,True,USD,"Day One Biopharmaceuticals, Inc",27.83,26.4,35.0,8,8,NasdaqGS,USD,28.1,110836,121671,10.576,0.6150983,17.194 - 28.42,-0.6499996,-0.022871204,17.194,28.42,-0.059999466,-0.21559277,1630503554,27.77,28.32,27.25 - 28.32,27.25,3124,-29.371,-1.52,-3.11,-8.929261,5.034,24.087639,3.6823616,0.1528735,22.64918,5.120821,0.22609301,1719765632,-18.269737,5.516488,15,0,2021-05-27,1.7 - Buy,False,REGULAR,1622122200000,2,NMS,"Day One Biopharmaceuticals, Inc.",finmb_704589075,America/New_York,EDT,-14400000,us_market,False,Day One Biopharmaceuticals,,18.43%,26.30%,28.42,17.19,24.09,22.65,110.84k,121.67k,61.93M,,16.17M,34.74%,46.15%,1.27M,19.26,5.16%,2.05%,972.42k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,,,,,,,-41.22M,-166.67M,-29.37,,310M,5.01,313k,0.10,67.79,5.03,-32.66M,,Value,94080-1930,Healthcare,29,"Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.",South San Francisco,650 484 0899,CA,1609372800,United States,http://dayonebio.com,86400,395 Oyster Point Boulevard,Biotechnology,Suite 217
t-1,DAWN,-68849000.0,61928900,12632000,,-16101000,4783000.0,-15182000,3454000,0,-16086000,-16086000,,-7000,,,,0,0,16086000,0,-15000,,-16101000,-15182000,3225000.0,-68849000.0,693000.0,160880000.0,2000000.0,3770000.0,-72024000.0,1690000.0,154870000.0,3066000.0,435000.0,158755000.0,686000.0,1175000.0,1175000.0,484000.0,128885000.0,-2720000.0,167660000.0,111142000.0,-9743000.0,49000.0,-872000.0,7626000.0,-8000000.0,,155689000.0,en-US,US,EQUITY,Nasdaq Real Time Price,True,USD,"Day One Biopharmaceuticals, Inc",27.83,26.4,35.0,8,8,NasdaqGS,USD,28.1,110836,121671,10.576,0.6150983,17.194 - 28.42,-0.6499996,-0.022871204,17.194,28.42,-0.059999466,-0.21559277,1630503554,27.77,28.32,27.25 - 28.32,27.25,3124,-29.371,-1.52,-3.11,-8.929261,5.034,24.087639,3.6823616,0.1528735,22.64918,5.120821,0.22609301,1719765632,-18.269737,5.516488,15,0,2021-05-27,1.7 - Buy,False,REGULAR,1622122200000,2,NMS,"Day One Biopharmaceuticals, Inc.",finmb_704589075,America/New_York,EDT,-14400000,us_market,False,Day One Biopharmaceuticals,,18.43%,26.30%,28.42,17.19,24.09,22.65,110.84k,121.67k,61.93M,,16.17M,34.74%,46.15%,1.27M,19.26,5.16%,2.05%,972.42k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,,,,,,,-41.22M,-166.67M,-29.37,,310M,5.01,313k,0.10,67.79,5.03,-32.66M,,Value,94080-1930,Healthcare,29,"Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.",South San Francisco,650 484 0899,CA,1609372800,United States,http://dayonebio.com,86400,395 Oyster Point Boulevard,Biotechnology,Suite 217
t-2,DAWN,,61928900,1437000,,-2409000,4783000.0,-1760000,872000,0,-2309000,-2309000,,-10000,,,,0,0,2309000,0,-100000,,-2409000,-1760000,,,,,,,,,,,,,,,,112000.0,128885000.0,205000.0,167660000.0,-1893000.0,-1888000.0,46000.0,-872000.0,-491000.0,-5000.0,-5000.0,,en-US,US,EQUITY,Nasdaq Real Time Price,True,USD,"Day One Biopharmaceuticals, Inc",27.83,26.4,35.0,8,8,NasdaqGS,USD,28.1,110836,121671,10.576,0.6150983,17.194 - 28.42,-0.6499996,-0.022871204,17.194,28.42,-0.059999466,-0.21559277,1630503554,27.77,28.32,27.25 - 28.32,27.25,3124,-29.371,-1.52,-3.11,-8.929261,5.034,24.087639,3.6823616,0.1528735,22.64918,5.120821,0.22609301,1719765632,-18.269737,5.516488,15,0,2021-05-27,1.7 - Buy,False,REGULAR,1622122200000,2,NMS,"Day One Biopharmaceuticals, Inc.",finmb_704589075,America/New_York,EDT,-14400000,us_market,False,Day One Biopharmaceuticals,,18.43%,26.30%,28.42,17.19,24.09,22.65,110.84k,121.67k,61.93M,,16.17M,34.74%,46.15%,1.27M,19.26,5.16%,2.05%,972.42k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,,,,,,,-41.22M,-166.67M,-29.37,,310M,5.01,313k,0.10,67.79,5.03,-32.66M,,Value,94080-1930,Healthcare,29,"Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.",South San Francisco,650 484 0899,CA,1609372800,United States,http://dayonebio.com,86400,395 Oyster Point Boulevard,Biotechnology,Suite 217
t-3,DAWN,-10673000.0,61928900,961000,,-1992000,4783000.0,-1535000,808000,0,-1769000,-1769000,,-3000,,,,0,0,1769000,0,-223000,,-1992000,-1535000,,-10673000.0,,,,,,,,,,,,,,43000.0,128885000.0,-429000.0,167660000.0,-2173000.0,-2085000.0,14000.0,-872000.0,-178000.0,-88000.0,-88000.0,,en-US,US,EQUITY,Nasdaq Real Time Price,True,USD,"Day One Biopharmaceuticals, Inc",27.83,26.4,35.0,8,8,NasdaqGS,USD,28.1,110836,121671,10.576,0.6150983,17.194 - 28.42,-0.6499996,-0.022871204,17.194,28.42,-0.059999466,-0.21559277,1630503554,27.77,28.32,27.25 - 28.32,27.25,3124,-29.371,-1.52,-3.11,-8.929261,5.034,24.087639,3.6823616,0.1528735,22.64918,5.120821,0.22609301,1719765632,-18.269737,5.516488,15,0,2021-05-27,1.7 - Buy,False,REGULAR,1622122200000,2,NMS,"Day One Biopharmaceuticals, Inc.",finmb_704589075,America/New_York,EDT,-14400000,us_market,False,Day One Biopharmaceuticals,,18.43%,26.30%,28.42,17.19,24.09,22.65,110.84k,121.67k,61.93M,,16.17M,34.74%,46.15%,1.27M,19.26,5.16%,2.05%,972.42k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,,,,,,,-41.22M,-166.67M,-29.37,,310M,5.01,313k,0.10,67.79,5.03,-32.66M,,Value,94080-1930,Healthcare,29,"Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.",South San Francisco,650 484 0899,CA,1609372800,United States,http://dayonebio.com,86400,395 Oyster Point Boulevard,Biotechnology,Suite 217
